DarioHealth Corp.

DarioHealth Corp.

NNASDAQ:DRIO
1.15
USD
-0.11
(-8.73%)
-5.49EPS
48.46MMarket Cap
Mar 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
42.32
173.48
215.5
214.79
126.32
66.71
25.41
24.73
23.4
14.35
11.03
5.61
3.23
Basic EPS, GAAP
-25,010.77
-13,092.12
-1,505.48
-891.6
-664.64
-312.58
-184.38
-111.02
-94.95
-54.02
-44.77
-16.71
-15.5
-6.97
Free Cash Flow per Basic Share
-16,159.78
-7,588.38
-1,346.33
-706.31
-449.27
-197.17
-139.65
-59.88
-61.08
-40.97
-21.83
-15.78
-6.55
-3.92
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-154.4
-2,349.16
-217.09
-457.96
112.01
97.52
169.03
69.34
103.24
62.2
42.77
37.52
9.84
7.5
Tangible Book Value per Share
-154.4
-2,349.16
-217.09
-457.96
112.01
97.52
169.03
69.34
37.95
22.11
8.16
-2.17
-0.79
-2.36
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
4
6
Sales/Revenue/Turnover
- -
- -
1
3
5
7
8
8
21
28
20
27
22
21
Operating Margin (%)
- -
-21,311.76
-935.36
-386.44
-278.9
-239.22
-234.22
-394.71
-372.9
-205.42
-276.09
-213.55
-163.94
-151.6
Depreciation Expense
1
1
- -
- -
- -
- -
- -
- -
4
5
5
7
3
2
Net Income, GAAP
-14
-13
-7
-11
-16
-18
-18
-29
-77
-62
-59
-43
-42
-36
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-25,249.02
-867.8
-388.41
-304.51
-240.78
-234.63
-388.66
-374.21
-224.88
-292
-158.09
-186.56
-169.87
Working Capital
1
- -
3
- -
3
8
18
27
31
46
35
24
26
13
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
19
25
24
31
32
Total Equity
- -
-3
1
-7
4
9
19
28
86
80
58
72
68
55
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-284.41
-150.19
-140.73
-138.55
-77.12
-91.95
-62.97
-88.23
-76.05

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
1
LT Borrowings
31
31
31
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
79
59
48

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
35
29
22
Cash, Cash Equivalents & STI
26
20
14
Accounts Receivable, Net
2
2
2
Inventories
4
4
4
Total Current Liabilities
9
9
10
Payables & Accruals
5
8
8
ST Debt
- -
- -
1
Deferred Revenue
1
1
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-62.67%
37.65%
-5.69%
Free Cash Flow
25.39%
27.14%
-32.6%
Net Income, GAAP
28.25%
21.35%
-2.42%
Sales/Revenue/Turnover
56.52%
38.94%
-17.31%
Total Cash Common Dividend
- -
-258.44%
-1,234.33%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
6
7
8
27
2025
7
5
5
5
22
2026
6
5
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.35
-2.46
-7.23
-6.39
-16.71
2025
-5.94
-7.48
-6.01
-1.48
-15.5
2026
-1.25
-0.85
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Erez Raphael
Full Time Employees
165
Sector
Health technology
Industry
Medical specialties
Address
322 W. 57th Street New York NY United States 10019
IPO Date
Mar 14, 2016
Business
DarioHealth Corp. (NASDAQ: DRIO) operates as a global digital therapeutics company that delivers personalized, evidence-based interventions through its user-centric platform, integrating software, connected devices, AI-driven data analytics, and one-on-one coaching to manage chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain such as posture, injury, and pain issues, and behavioral health conditions like anxiety, depression, and stress; core offerings encompass the Dario mobile app with real-time monitoring and hypo-alerts, DarioEngage population health management platform, Dario Loop AI journey engine, Dario Tools smartphone-integrated devices, digital coaching via chat with educational content, and expanded GLP-1 solutions with prescribing capabilities, targeting health plans, self-insured employers, providers, pharmaceutical companies, and direct-to-consumer markets primarily through B2B2C channels in the United States, Canada, the European Union, Australia, and New Zealand. Founded in 2011 as LabStyle Innovations Corp. in Caesarea, Israel, with principal executive offices in New York and ongoing R&D in Israel, the company focuses on disrupting traditional episodic healthcare with continuous, customized care to drive sustainable behavior change and clinical outcomes like HbA1c reductions and risk diminutions. Recent developments include the strategic acquisition of Twill in early 2024 to broaden multi-condition offerings and achieve immediate scale with top national health plans and Fortune 100 employers, a $25.6 million private placement in 2025 to fund growth toward operational cash flow positivity by year-end, new partnerships such as with BCBS launched in January 2025 and MediOrbis for GLP-1 expansions, signing of four new employer contracts and 79 new accounts exceeding 2025 targets as of December 2025, and contracts covering over 2.8 million eligible lives with demonstrated revenue growth including 111% year-over-year in Q3 2024.

Company News

  • Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Cla

  • Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data

  • DarioHealth Corp. (DRIO) Q3 2026 Earnings Call Transcript

  • DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates

  • DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction

  • DarioHealth (NASDAQ:DRIO) and HealthStream (NASDAQ:HSTM) Critical Survey

  • Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

  • DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026

  • Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program

  • DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

  • Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

  • DarioHealth (NASDAQ:DRIO) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

  • Pro Medicus (OTCMKTS:PMCUF) versus DarioHealth (NASDAQ:DRIO) Head to Head Survey

  • Contrasting DarioHealth (NASDAQ:DRIO) and Phreesia (NYSE:PHR)

  • DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript

  • DarioHealth Q2 Earnings Call Highlights

  • DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates

  • DarioHealth Reports Second Quarter 2026 Financial Results

  • Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

  • DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026